<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01853605</url>
  </required_header>
  <id_info>
    <org_study_id>410CA-002</org_study_id>
    <nct_id>NCT01853605</nct_id>
  </id_info>
  <brief_title>NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Access Post-Approval Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-approval study of the safety and effectiveness of NATRELLE® 410 Highly Cohesive
      Anatomically Shaped Silicone-Filled Breast Implants (Styles 410 FM, FF, MM, or MF) for breast
      augmentation, reconstruction, or revision
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was discontinued following product approval.
  </why_stopped>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Satisfaction With Breast Implants on a 5-Point Scale</measure>
    <time_frame>5 years</time_frame>
    <description>Subject satisfaction with each breast implant is assessed on the following 5-point scale: (Definitely Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, and Definitely Dissatisfied). Satisfaction is reported for subject's assessing satisfaction as definitely satisfied and somewhat satisfied. The worst response is used if the subject reports different responses for the left and right breasts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator Satisfaction With Breast Implants on a 5-Point Scale</measure>
    <time_frame>5 years</time_frame>
    <description>Investigator satisfaction with each breast implant is assessed on the following 5-point scale: (Definitely Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, and Definitely Dissatisfied). Satisfaction is reported for Investigator's assessing satisfaction as definitely satisfied and somewhat satisfied. The worst response is used if the Investigator reports different responses for the left and right breasts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Complications</measure>
    <time_frame>5 years</time_frame>
    <description>Local complications are the cumulative complications occurring in at least 5% of subjects in 1 or more cohorts over the duration of the study. The Kaplan-Meier risk rate is presented.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3811</enrollment>
  <condition>Breast Augmentation</condition>
  <condition>Breast Reconstruction</condition>
  <condition>Breast Implant Revision</condition>
  <arm_group>
    <arm_group_label>Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women undergoing breast augmentation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women undergoing breast reconstruction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revision-Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women undergoing revision of previous breast augmentation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revision-Reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women undergoing revision of previous breast reconstruction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anatomically shaped silicone gel-filled breast implants</intervention_name>
    <description>Surgical implant</description>
    <arm_group_label>Augmentation</arm_group_label>
    <arm_group_label>Reconstruction</arm_group_label>
    <arm_group_label>Revision-Augmentation</arm_group_label>
    <arm_group_label>Revision-Reconstruction</arm_group_label>
    <other_name>NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (Styles 410 FM, FF, MM, or MF)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For entry in this study, subjects must have been enrolled in the 410 CA Clinical Study or
        410 CARE Clinical Study under the inclusion criteria listed below and received NATRELLE®
        410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants Styles 410 FM, FF,
        MM, or MF in 1 (for unilateral breast reconstruction or revision) or both breasts.

          -  Female, age 18 or older

          -  Present with one or more of the following conditions:

          -  Primary breast augmentation (i.e., no previous breast implant surgery) indicated for
             subject dissatisfaction, with size or shape of breast (e.g., mammary hypoplasia),
             asymmetry, ptosis, or aplasia

          -  Primary breast reconstruction (i.e., no previous breast implant surgery other than
             implantation of tissue expanders or contralateral augmentation for asymmetry)
             indicated, in the affected breast, for mastectomy for cancer, prophylactic mastectomy,
             or breast trauma (resulting in mastectomy) and for the unaffected breast,
             contralateral asymmetry (may be performed on the date of the mastectomy or the date
             when permanent implants are placed in the reconstructed breast)

          -  Breast implant revision surgery (i.e., removal and replacement of breast implants)
             indicated for previous augmentation or reconstruction with silicone-filled or
             saline-filled breast implants

          -  Has adequate tissue available to cover implants

          -  Willing to undergo MRI at the specified follow-up visit for subjects at MRI designated
             sites and be eligible for MRI (e.g., no implanted metal or metal devices, no history
             of severe claustrophobia)

        Exclusion Criteria:

        For entry in this study, subjects must have been enrolled in the 410 CA Clinical Study or
        410 CARE Clinical Study and met the exclusion criteria listed below but not received any
        NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled 410 X- or L-Style Breast
        Implants

          -  Does not have advanced fibrocystic disease considered to be premalignant without
             accompanying subcutaneous mastectomy

          -  Does not have existing carcinoma of the breast, without mastectomy

          -  Does not have abscess or infection in the body at the time of enrollment

          -  Is not pregnant or nursing

          -  Does not have any disease, including uncontrolled diabetes (e.g., HbA1c &gt; 8%), that is
             clinically known to impact wound healing ability

          -  Does not show tissue characteristics that are clinically incompatible with
             mammaplasty, such as tissue damage resulting from radiation, inadequate tissue,
             compromised vascularity, or ulceration

          -  Does not have or is under treatment for any condition that may constitute an
             unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems)

          -  Does not show psychological characteristics that may be incompatible with the surgical
             procedure and the prosthesis, such as inappropriate attitude or motivation (e.g., body
             dysmorphic disorder)

          -  Is not willing to undergo further surgery for revision, if medically required
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <results_first_submitted>July 16, 2015</results_first_submitted>
  <results_first_submitted_qc>July 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2015</results_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was discontinued following product approval.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Augmentation</title>
          <description>Women undergoing breast augmentation.</description>
        </group>
        <group group_id="P2">
          <title>Revision-Augmentation</title>
          <description>Women undergoing revision of previous breast augmentation.</description>
        </group>
        <group group_id="P3">
          <title>Reconstruction</title>
          <description>Women undergoing breast reconstruction.</description>
        </group>
        <group group_id="P4">
          <title>Revision-Reconstruction</title>
          <description>Women undergoing revision of previous breast reconstruction.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1939"/>
                <participants group_id="P2" count="693"/>
                <participants group_id="P3" count="751"/>
                <participants group_id="P4" count="428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1939"/>
                <participants group_id="P2" count="693"/>
                <participants group_id="P3" count="751"/>
                <participants group_id="P4" count="428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Augmentation</title>
          <description>Women undergoing breast augmentation.</description>
        </group>
        <group group_id="B2">
          <title>Revision-Augmentation</title>
          <description>Women undergoing revision of previous breast augmentation.</description>
        </group>
        <group group_id="B3">
          <title>Reconstruction</title>
          <description>Women undergoing breast reconstruction.</description>
        </group>
        <group group_id="B4">
          <title>Revision-Reconstruction</title>
          <description>Women undergoing revision of previous breast reconstruction.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1939"/>
            <count group_id="B2" value="693"/>
            <count group_id="B3" value="751"/>
            <count group_id="B4" value="428"/>
            <count group_id="B5" value="3811"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.0" spread="8.65"/>
                    <measurement group_id="B2" value="46.2" spread="9.96"/>
                    <measurement group_id="B3" value="49.8" spread="10.03"/>
                    <measurement group_id="B4" value="53.5" spread="9.11"/>
                    <measurement group_id="B5" value="42.5" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1939"/>
                    <measurement group_id="B2" value="693"/>
                    <measurement group_id="B3" value="751"/>
                    <measurement group_id="B4" value="428"/>
                    <measurement group_id="B5" value="3811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Satisfaction With Breast Implants on a 5-Point Scale</title>
        <description>Subject satisfaction with each breast implant is assessed on the following 5-point scale: (Definitely Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, and Definitely Dissatisfied). Satisfaction is reported for subject's assessing satisfaction as definitely satisfied and somewhat satisfied. The worst response is used if the subject reports different responses for the left and right breasts.</description>
        <time_frame>5 years</time_frame>
        <population>Evaluable population: all enrolled subjects implanted with the NATRELLE 410 original style implants, who completed the 5 year follow-up visit, and had data at the time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women undergoing breast augmentation.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women undergoing revision of previous breast augmentation.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women undergoing breast reconstruction.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women undergoing revision of previous breast reconstruction.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction With Breast Implants on a 5-Point Scale</title>
          <description>Subject satisfaction with each breast implant is assessed on the following 5-point scale: (Definitely Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, and Definitely Dissatisfied). Satisfaction is reported for subject's assessing satisfaction as definitely satisfied and somewhat satisfied. The worst response is used if the subject reports different responses for the left and right breasts.</description>
          <population>Evaluable population: all enrolled subjects implanted with the NATRELLE 410 original style implants, who completed the 5 year follow-up visit, and had data at the time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1929"/>
                <count group_id="O2" value="688"/>
                <count group_id="O3" value="740"/>
                <count group_id="O4" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definitely Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1772"/>
                    <measurement group_id="O2" value="559"/>
                    <measurement group_id="O3" value="542"/>
                    <measurement group_id="O4" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="145"/>
                    <measurement group_id="O4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Investigator Satisfaction With Breast Implants on a 5-Point Scale</title>
        <description>Investigator satisfaction with each breast implant is assessed on the following 5-point scale: (Definitely Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, and Definitely Dissatisfied). Satisfaction is reported for Investigator's assessing satisfaction as definitely satisfied and somewhat satisfied. The worst response is used if the Investigator reports different responses for the left and right breasts.</description>
        <time_frame>5 years</time_frame>
        <population>Evaluable population: all enrolled subjects implanted with the NATRELLE 410 original style implants, who completed the 5 year follow-up visit, and had data at the time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women undergoing breast augmentation.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women undergoing revision of previous breast augmentation.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women undergoing breast reconstruction.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women undergoing revision of previous breast reconstruction.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Satisfaction With Breast Implants on a 5-Point Scale</title>
          <description>Investigator satisfaction with each breast implant is assessed on the following 5-point scale: (Definitely Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, and Definitely Dissatisfied). Satisfaction is reported for Investigator's assessing satisfaction as definitely satisfied and somewhat satisfied. The worst response is used if the Investigator reports different responses for the left and right breasts.</description>
          <population>Evaluable population: all enrolled subjects implanted with the NATRELLE 410 original style implants, who completed the 5 year follow-up visit, and had data at the time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1922"/>
                <count group_id="O2" value="689"/>
                <count group_id="O3" value="745"/>
                <count group_id="O4" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definitely Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1798"/>
                    <measurement group_id="O2" value="560"/>
                    <measurement group_id="O3" value="564"/>
                    <measurement group_id="O4" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="141"/>
                    <measurement group_id="O4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Local Complications</title>
        <description>Local complications are the cumulative complications occurring in at least 5% of subjects in 1 or more cohorts over the duration of the study. The Kaplan-Meier risk rate is presented.</description>
        <time_frame>5 years</time_frame>
        <population>Evaluable population: all enrolled subjects implanted with the NATRELLE 410 original style implants who completed the 5 year follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women undergoing breast augmentation.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women undergoing revision of previous breast augmentation.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women undergoing breast reconstruction.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women undergoing revision of previous breast reconstruction.</description>
          </group>
        </group_list>
        <measure>
          <title>Local Complications</title>
          <description>Local complications are the cumulative complications occurring in at least 5% of subjects in 1 or more cohorts over the duration of the study. The Kaplan-Meier risk rate is presented.</description>
          <population>Evaluable population: all enrolled subjects implanted with the NATRELLE 410 original style implants who completed the 5 year follow-up visit.</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="693"/>
                <count group_id="O3" value="751"/>
                <count group_id="O4" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Capsular Contracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" lower_limit="2.56" upper_limit="4.16"/>
                    <measurement group_id="O2" value="6.33" lower_limit="4.74" upper_limit="8.45"/>
                    <measurement group_id="O3" value="6.48" lower_limit="4.92" upper_limit="8.51"/>
                    <measurement group_id="O4" value="7.29" lower_limit="5.19" upper_limit="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymmetry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.51" upper_limit="1.35"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.39" upper_limit="1.93"/>
                    <measurement group_id="O3" value="5.94" lower_limit="4.46" upper_limit="7.90"/>
                    <measurement group_id="O4" value="3.32" lower_limit="1.98" upper_limit="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse event (AE) data experienced by ≥5% of subjects are recorded as an outcome measure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Augmentation</title>
          <description>Women undergoing breast augmentation.</description>
        </group>
        <group group_id="E2">
          <title>Revision-Augmentation</title>
          <description>Women undergoing revision of previous breast augmentation.</description>
        </group>
        <group group_id="E3">
          <title>Reconstruction</title>
          <description>Women undergoing breast reconstruction.</description>
        </group>
        <group group_id="E4">
          <title>Revision-Reconstruction</title>
          <description>Women undergoing revision of previous breast reconstruction.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1939"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1939"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allergan Inc.,</name_or_title>
      <organization>Allergan, Inc</organization>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

